CTL Escape Mediated by Proteasomal Destruction of an HIV-1 Cryptic Epitope

INSERM, UMR-S945, Université Pierre et Marie Curie (UPMC), Paris, France.
PLoS Pathogens (Impact Factor: 8.06). 05/2011; 7(5):e1002049. DOI: 10.1371/journal.ppat.1002049
Source: PubMed

ABSTRACT Cytotoxic CD8+ T cells (CTLs) play a critical role in controlling viral infections. HIV-infected individuals develop CTL responses against epitopes derived from viral proteins, but also against cryptic epitopes encoded by viral alternative reading frames (ARF). We studied here the mechanisms of HIV-1 escape from CTLs targeting one such cryptic epitope, Q9VF, encoded by an HIVgag ARF and presented by HLA-B*07. Using PBMCs of HIV-infected patients, we first cloned and sequenced proviral DNA encoding for Q9VF. We identified several polymorphisms with a minority of proviruses encoding at position 5 an aspartic acid (Q9VF/5D) and a majority encoding an asparagine (Q9VF/5N). We compared the prevalence of each variant in PBMCs of HLA-B*07+ and HLA-B*07- patients. Proviruses encoding Q9VF/5D were significantly less represented in HLA-B*07+ than in HLA-B*07- patients, suggesting that Q9FV/5D encoding viruses might be under selective pressure in HLA-B*07+ individuals. We thus analyzed ex vivo CTL responses directed against Q9VF/5D and Q9VF/5N. Around 16% of HLA-B*07+ patients exhibited CTL responses targeting Q9VF epitopes. The frequency and the magnitude of CTL responses induced with Q9VF/5D or Q9VF/5N peptides were almost equal indicating a possible cross-reactivity of the same CTLs on the two peptides. We then dissected the cellular mechanisms involved in the presentation of Q9VF variants. As expected, cells infected with HIV strains encoding for Q9VF/5D were recognized by Q9VF/5D-specific CTLs. In contrast, Q9VF/5N-encoding strains were neither recognized by Q9VF/5N- nor by Q9VF/5D-specific CTLs. Using in vitro proteasomal digestions and MS/MS analysis, we demonstrate that the 5N variation introduces a strong proteasomal cleavage site within the epitope, leading to a dramatic reduction of Q9VF epitope production. Our results strongly suggest that HIV-1 escapes CTL surveillance by introducing mutations leading to HIV ARF-epitope destruction by proteasomes.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The degradation of HIV-derived proteins into epitopes displayed by MHC-I or MHC-II are the first events leading to the priming of HIV-specific immune responses and to the recognition of infected cells. Despite a wealth of information about peptidases involved in protein degradation, our knowledge of epitope presentation during HIV infection remains limited. Here we review current data on HIV protein degradation linking epitope production and immunodominance, viral evolution and impaired epitope presentation. We propose that an in-depth understanding of HIV antigen processing and presentation in relevant primary cells could be exploited to identify signatures leading to efficient or inefficient epitope presentation in HIV proteomes, and to improve the design of immunogens eliciting immune responses efficiently recognizing all infected cells.
    Viruses 08/2014; 6(8):3271-3292. DOI:10.3390/v6083271 · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunoproteasomes are considered to be optimized to process antigens and to alter the peptide repertoire by generating a qualitatively different set of MHC-class I epitopes. Whether immunoproteasomes, at the biochemical level, influence the quality rather than the quantity of the immunogenic peptide pool is still unclear. Here, we quantified the cleavage site usage by human standard-, immuno-proteasomes and proteasomes from immuno-subunit deficient mice, as well as the peptides generated from model polypeptides. We show in this study that the different proteasome isoforms can exert significant quantitative differences in the cleavage site usage and MHC class I-restricted epitope production. However, independent of the proteasome isoform and substrates studied, no evidence was obtained for the abolishment of the specific cleavage site usage, or for differences in the quality of the peptides generated. Thus, we conclude that the observed differences in MHC class I-restricted antigen presentation between the standard- and the immuno-proteasomes are due to quantitative differences in the proteasome-generated antigenic peptides.This article is protected by copyright. All rights reserved
    European Journal of Immunology 12/2014; 44(12). DOI:10.1002/eji.201444902 · 4.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although it is established that CD8 T-cell immunity is critical for the control of HIV replication in vivo, the key factors that determine antiviral efficacy are yet to be fully elucidated. Antigen-sensitivity and T-cell receptor (TCR) avidity have been identified as potential determinants of CD8 T-cell efficacy. However, there is no general consensus in this regard because the relationship between these parameters and the control of HIV infection has been established primarily in the context of immunodominant CD8 T-cell responses against the Gag263-272 KK10 epitope restricted by HLA-B27. To investigate the relationship between antigen-sensitivity, TCR avidity and HIV-suppressive capacity in vitro across epitope specificities and HLA class I restriction elements, we used a variety of techniques to study CD8 T-cell clones specific for Nef73-82 QK10 and Gag20-29 RY10, both restricted by HLA-A3, alongside CD8 T-cell clones specific for Gag263-272 KK10. For each targeted epitope, the linked parameters of antigen-sensitivity and TCR avidity correlated directly with antiviral efficacy. However, marked differences in HIV-suppressive capacity were observed between epitope specificities, HLA class I restriction elements and viral isolates. Collectively, these data emphasize the central role of the TCR as a determinant of CD8 T-cell efficacy and demonstrate that the complexities of antigen recognition across epitope and HLA class I boundaries can confound simple relationships between TCR engagement and HIV suppression.
    AIDS (London, England) 12/2013; 28(4). DOI:10.1097/QAD.0000000000000175 · 6.56 Impact Factor

Full-text (2 Sources)

Available from
May 20, 2014